Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder

Launched by UNIVERSITY OF CALGARY · Aug 25, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD can make it hard for children to pay attention, control their impulses, and manage their energy levels and emotions. The researchers want to see if a technique called repetitive transcranial magnetic stimulation (rTMS) can help reduce these symptoms and improve the quality of life for kids with ADHD.

To participate, children aged 10 to 15 who have been diagnosed with ADHD and have an IQ above 80 may be eligible. They should have been on the same medication for at least three months, if they are taking any. However, those with certain conditions, like severe mood disorders or autism, or who have metal implants, cannot take part in the trial. If eligible, participants can expect to undergo rTMS treatment, which is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. The trial is not yet recruiting, but it represents an opportunity to explore new ways to help children manage ADHD symptoms more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of ADHD
• • 2. 10-15 years old
• • 3. IQ greater than 80
• • 4. English fluency (to enable consent/assent)
• • 5. If on medication, must have been on the same type and dosage for at least 3 months.
• Exclusion Criteria:
• • 1. Diagnosis of mania, psychosis, or bipolar disorder
• • 2. Impediments to TMS or MRI (i.e. metal implants in body)
• • 3. Prior electroconvulsive therapy or vagus nerve stimulation
• • 4. Diagnosis of Autism Spectrum Disorder.